Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Traeger, Inc. Q4 2025 Earnings Call - Project Gravity reshapes business, trims revenue now for stronger margins later
Traeger closed fiscal 2025 with revenue of $560 million and Adjusted EBITDA of $70 million, beating guidance while navigating tariff-driven volatility. Management framed 2026 as a transition year, tra...
- Full year 2025 revenue was $560 million, above the high end of guidance, and Adjusted EBITDA was $70 million, in the upper half of the guided range.
- 2026 guidance is a marked step down: revenue $465 million-$485 million and Adjusted EBITDA $50 million-$60 million, with management calling 2026 a foundational, transition year.
- Project Gravity has grown in scope, now expected to deliver $64 million-$70 million of total run-rate value, including an incremental $6 million-$12 million of SKU and pricing capture that mostly accrues in 2027-2028.
- +16 more takeaways
OptimizeRx Q4 2025 Earnings Call - Profitability Levers Strong, But MFN Headwinds and Managed-Services Drop Cloud Early-2026 Revenue
OptimizeRx closed FY2025 with solid operating leverage, beating expectations in Q4 with $32.2 million in revenue and $12.0 million adjusted EBITDA, and full-year revenue of $109.4 million with adjuste...
- Q4 2025 revenue $32.2 million, adjusted EBITDA $12.0 million; FY2025 revenue $109.4 million, adjusted EBITDA $24.3 million.
- Q4 gross margin rose to 74.8%, driven by an unusually favorable mix of specialty messaging and channel partners; management expects mid-60% gross margins in 2026.
- Company generated nearly $19 million in operating free cash flow for 2025, raising cash and short-term investments to $23.4 million versus $13.4 million a year earlier.
- +11 more takeaways
Owlet Q4 2025 Earnings Call - Subscription Momentum: 110,000 Owlet360 Subscribers and Path to Recurring Revenue Growth
Owlet closed 2025 with a record year, driven by the launch and rapid scaling of its Owlet360 subscription and the Dream product suite. Full year revenue hit $105.7 million, up 35.4% year over year, an...
- Owlet reported Q4 2025 revenue of $26.6 million, up 29.6% year over year, and full year 2025 revenue of $105.7 million, up 35.4% versus 2024.
- Owlet360 subscription reached over 110,000 paying subscribers as of early March, marking the first full year of the service since its January 2025 launch.
- Full year 2025 gross margin was a record 50.6% despite tariff headwinds, Q4 gross margin was 47.6% which included an estimated 510 basis point tariff impact.
- +17 more takeaways
AudioEye Q4 2025 Earnings Call - Guides 30% Adjusted EBITDA Growth in 2026, Betting on AI Efficiency and ARR Acceleration
AudioEye closed 2025 with streaky momentum and cleaner economics. The company reported its 40th consecutive quarter of sequential revenue growth, record full-year revenue, and a 35% jump in adjusted E...
- AudioEye reported its 40th consecutive quarter of sequential revenue growth and record full-year 2025 revenue.
- Adjusted EBITDA for 2025 was a record $9.1 million, up approximately 35% year-over-year, with an adjusted EBITDA margin of 22%.
- Management guides 2026 adjusted EBITDA to grow by at least 30%, implying at least $11.8 million for the year and a run rate target of $15 million by year-end driven by AI efficiencies.
- +14 more takeaways
Atea Pharmaceuticals Fourth Quarter 2025 Earnings Call - Phase 3 HCV readouts set to define 2026 with cash runway through 2027
Atea says 2026 is a make-or-break year. The company expects top-line results from its global phase 3 HCV program this year, with C-BEYOND readout midyear and C-FORWARD by year-end, while maintaining r...
- Company-wide focus for 2026 is delivery of phase 3 HCV top-line readouts: C-BEYOND midyear and C-FORWARD by year-end.
- HCV regimen under study is bemnifosbuvir plus ruzasvir, evaluated head-to-head versus sofosbuvir/velpatasvir (Epclusa).
- Atea states its global phase 3 program will enroll more than 1,760 patients across two trials, C-BEYOND (North America) and C-FORWARD (rest of world).
- +13 more takeaways
a.k.a. Brands Holding Corp. Q4 FY2025 Earnings Call - Guides FY2026 as an Inflection Year with Mid-Single Digit Sales Growth and Material EBITDA Expansion
a.k.a. Brands closed FY25 with modest top-line growth and a recalibrated foundation, and management is calling 2026 an inflection year. The company grew net sales 4.4% to $600 million, sharpened inven...
- FY25 net sales grew 4.4% to $600.0 million, 5.0% on a constant currency basis.
- Management calls FY26 an inflection year, guiding net sales of $625 million to $635 million, and adjusted EBITDA of $27 million to $29 million.
- Tariffs were a material headwind in FY25, management estimates roughly 100 basis points of gross margin pressure from tariff-related sourcing costs.
- +11 more takeaways
TriSalus Life Sciences Fourth Quarter 2025 Earnings Call - $46M Raise, Doubling Sales Force and Reaffirming $60-62M 2026 Revenue with Back-Loaded Growth
TriSalus closed 2025 with strong top-line momentum, raising $46 million in a well-subscribed public offering and reporting Q4 revenue of $13.2 million and full-year revenue of $45.2 million. Managemen...
- Q4 2025 revenue was $13.2 million, up 60% year over year; full-year 2025 revenue was $45.2 million, up 53% year over year.
- TriSalus completed a public offering in February that raised $46 million in gross proceeds, the deal was more than two times oversubscribed and brought in fundamental healthcare investors.
- Management reaffirmed 2026 revenue guidance at $60 million to $62 million, and expects roughly 40% of 2026 revenue in H1 and 60% in H2 due to onboarding and territory realignment.
- +11 more takeaways
AerSale Q4 2025 Earnings Call - Shift to recurring revenue and disciplined feedstock buying drives margin expansion
AerSale closed 2025 with improving profitability despite a stumble in headline revenue. Q4 adjusted EBITDA rose to $15.2 million, up 17.1% year over year, while full year adjusted EBITDA surged to $46...
- Q4 adjusted EBITDA was $15.2 million, up 17.1% versus Q4 2024.
- Full year 2025 adjusted EBITDA rose to $46.1 million, up 38.2% year over year; full year revenue was $335.3 million, down 2.8%.
- Q4 revenue was $90.9 million, down 4% YoY; management says excluding flight equipment sales revenue increased about 9.8%.
- +12 more takeaways
Inuvo, Inc. Q4 2025 Earnings Call - IntentKey pivot targets higher-margin data and enterprise deals as Platforms revenue rebalances
Inuvo reported a sharp fourth quarter platform revenue pullback while pushing a strategic pivot toward IntentKey, its AI-driven intent product, as the path to higher-margin, recurring data and enterpr...
- Q4 2025 revenue was $14.3 million, a 46% decline versus Q4 2024, driven by an intentional pullback in platform products.
- Q4 gross profit fell to $9.5 million, down 56% year over year, and Q4 operating loss was $1.2 million.
- Q4 net loss was $594,000, or $0.04 per share, while adjusted EBITDA for the quarter was $360,000.
- +15 more takeaways
BioLargo 2025 Annual Earnings Call - Commercial inflection as Clyra launches and EPA monitors AEC PFAS demo
BioLargo frames 2025 as a pivot year, moving from development to commercialization across four proprietary platforms. Management points to concrete validation events: Clyra Medical shipped its first p...
- Company filed its 10-K and positions 2025 as a decisive transition from R&D to commercialization across four platforms: Clyra Medical, Cellinity Battery, AEC Water Treatment, and ONM Environmental.
- BioLargo retains significant equity in its subsidiaries, reported ownership stakes ranging from 49% to 100%, and receives a 6% royalty on sales as a recurring corporate revenue stream.
- Clyra Medical: ViaCLYR is FDA 510(k) cleared, presented clinical data at the 48th Annual Boswick Symposium, and the company has an exclusive distribution agreement with a large distributor, with its first commercial stocking order shipped and paid.
- +12 more takeaways